explore -WSS

explore

author：fashion 2025-09-30 00:50:21 - browse：71886

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Cancer drug shortages should be causing more outrage
Next article： New clues to why women have higher risk of autoimmune disorders

WSS

How generative AI ratchets up security threats for health systems

Cherokee Nation medical school graduates its first class

The White House hikes tariffs on plastic syringes made in China

Philips to halt sales of sleep apnea machines in U.S.

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Wegovy leads to weight loss. Can it treat depression, too?

entertainment

explore

explore

How one medical school became remarkably diverse

Obesity drug from Roche shows promise in early study

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

United colonoscopy coverage change 'may cost lives,' doctors say

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Moonlake's readout produced a cash windfall. Risks remain

Ripples from Flovent's discontinuation is killing children with asthma

Dobbs anniversary: the lost opportunity of abortion as health care

The United States must get value

hotspot

Biogen walks away from Aduhelm, years after polarizing approval

Cherokee Nation medical school graduates its first class

Free medical tuition alone isn't enough to close gaps in primary care

What a koala virus tells us about the human genome

Boston competes with Raleigh

FTC sues over Novant Health acquisition of two N.C. hospitals

Wikipedia

hotspot

entertainment

knowledge